News & Events about Ac Immune Sa.
AC Immune Showcasing Precision Medicine Programs at AAIC 2023 Lausanne, Switzerland, July 3, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations at the annual Alzheimers ...
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimers disease (AD) cohort in ABATE Phase 1b/2 trial;Further ABATE immunogenicity and safety data in higher dose AD ...
AC Immune at AD/PD 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline Ten presentations at the International Conference on Alzheimers & Parkinsons Diseases (AD/PDTM)AC Immunes Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimers ...
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023ACI-24.060 anti-amyloid-beta vaccine for ...
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 Lausanne, Switzerland, March 8, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will ...